Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS Framework Agreement, Branded Medicines for London and South of England

NHS England

This public procurement record has 2 releases in its history.

Award

17 Sep 2021 at 16:04

Award Notice
Tender

30 Apr 2021 at 15:19

Tender Notice
Summary of the contracting process

The NHS Framework Agreement for Branded Medicines, catering to London and the South of England, has reached the award stage and is now complete. The initiative is organised by NHS England, with procurement initiated on 1st September 2021 and scheduled to last until 31st August 2023, with the potential for up to 24 months of extensions at the discretion of the authority. The procurement process followed an open method, and the industry classification falls under pharmaceutical products (CPV code 33600000). The contract was awarded based on price criteria.

This tender presents significant opportunities for pharmaceutical companies, particularly those focused on branded medicines, to expand their market presence within the NHS framework. Businesses that are well-suited to compete include small and medium-sized enterprises as well as larger entities with the capability to deliver high-quality pharmaceutical products under the competitive bidding process. Given the extensive reach of NHS England, suppliers can expect substantial orders that can contribute to overall business growth.

How relevant is this notice?

Notice Information

Notice Title

NHS Framework Agreement, Branded Medicines for London and South of England

Notice Description

NHS Framework Agreement, Branded Medicines for London and South of England and NHS Framework for the Midlands & East and North of England Regions - Bevacizumab.

Lot Information

CM/PHR/20/5598/01 - NHS Framework LONDON Branded Medicines - Tranche B.

CM/PHR/20/5598/01 - NHS Framework for LONDON Branded Medicines - Tranche B.Period of framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 Months

Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5598/02 - NHS Framework LONDON Branded Medicines - Annual Tranche.

CM/PHR/20/5598/02 - NHS Framework for the LONDON Branded Medicines - Annual Tranche. Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/20/5598/05 - NHS Framework SOUTH of England Annual Tranche.

CM/PHR/20/5598/05 - NHS Framework for the SOUTH of England Annual Tranche.Period of Framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/20/5598/03 - NHS Framework SOUTH of England Tranche A.

CM/PHR/20/5598/03 - NHS Framework for the SOUTH of England Tranche A.Period of Framework: 1 September 2021 to 31 August 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/20/5598/04- NHS Framework SOUTH of England - Tranche B.

CM/PHR/20/5598/04- NHS Framework for SOUTH of England - Tranche B.Period of framework: 1 September 2021 to 31 August 2022 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 12 months

CM/PHR/20/5598/06 - NHS Framework Midlands & East and NofE - Bevacizumab

CM/PHR/20/5598/06 - NHS Framework for the Midlands & East and North of England Regions - Bevacizumab

Options: There will be an option to extend (at the Authority's discretion) for a period or periods up to a total of 6 months

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-02ac57
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/023223-2021
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£1,110,294,056 £1B-£10B
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
Not specified

Notice Dates

Publication Date
17 Sep 20214 years ago
Submission Deadline
4 Jun 2021Expired
Future Notice Date
Not specified
Award Date
19 Aug 20215 years ago
Contract Period
1 Sep 2021 - 28 Feb 2022 6-12 months
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Additional Buyers

The NHS Commissioning Board (operating under the name of NHS England)

Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LEEDS
Postcode
LS2 7UE
Postcode Area
Leeds
Country
England
Major Region (ITL 1)
TLE Yorkshire and The Humber
Basic Region (ITL 2)
TLE4 West Yorkshire
Small Region (ITL 3)
TLE42 Leeds
Delivery Location
TLI London
Local Authority
Leeds
Electoral Ward
Little London & Woodhouse
Westminster Constituency
Leeds Central and Headingley

Supplier Information

Number of Suppliers
42
Supplier Names

Accord-UK Ltd

Allergan

Amgen Ltd

AstraZeneca

Aventis Pharma ltd t/a Sanofi

Bayer Ltd

Biogen

Bristol Myers Squibb

CST Pharma Limited

Celltrion Healthcare United Kingdom Limited

Chugai

Daiichi Sankyo UK Ltd

Dr.Reddy's Laboratories (UK) Limited

Eli Lilly and Company Ltd

Ferring Pharmaceuticals Ltd

Gedeon Richter UK Ltd

Gilead Sciences Limited

Ipsen

Janssen-Cilag Ltd

Merck Serono Limited

Merck Sharpe and Dohme (UK) Limited

Merz

Morningside Pharmaeuticals

Mylan

Napp Pharmaceuticals Ltd

Novo Nordisk

Organon Pharmaceuticals UK Ltd

Pfizer Ltd

Pharmacosmos UK Ltd

Profile Pharma Ltd

Roche Products Ltd

Sandoz Ltd

Sobi (Swedish Orphan Biovitrum Ltd)

Takeda UK Ltd

Techdow Pharma England Ltd

Tetris Pharma Lts

Teva UK Limited

Thornton and Ross Ltd

UCB

UL Global Pharma

Vifor Pharma UK Ltd

Zentiva Pharma UK Ltd

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...